Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

American Journal of Kidney Diseases

Volumn 48, Issue 3, 2006, Pages

  Wienecke, Ralf ^a   Fackler, Ingrid ^a   Linsenmaier, Ulrich ^a   Mayer, Karin ^a   Licht, Thomas ^a   Kretzler, Matthias ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

angiomyolipoma; Rapamycin; tuberous sclerosis complex

Indexed keywords

RAPAMYCIN;

ADULT; ANGIOMYOLIPOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG REEXPOSURE; HUMAN; KIDNEY TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; ANGIOMYOLIPOMA; ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; SIROLIMUS; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 33747608873     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.05.018     Document Type: Article

References (14)

1. Roach E.S., Gomez M.R., and Northrup H. Tuberous sclerosis complex consensus conference. Revised clinical diagnostic criteria. J Child Neurol 13 (1998) 624-628
2. Dickinson M., Ruckle H., Beaghler M., and Hadley H.R. Renal angiomyolipoma. Optimal treatment based on size and symptoms. Clin Nephrol 49 (1998) 281-286
3. Kessler O.J., Gillon G., Neuman M., Engelstein D., Winkler H., and Baniel J. Management of renal angiomyolipoma. Analysis of 15 cases. Eur Urol 33 (1998) 572-575
4. Williams J.M., Racadio J.M., Johnson N.D., Donnelly L.F., and Bissler J.J. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis 47 (2006) 95-106
5. El-Hashemite N., Zhang H., Henske E.P., and Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signaling pathway in renal angiomyolipoma. Lancet 361 (2003) 1348-1349
6. Ma L., Chen Z., Erdjument-Bromage H., et al. Phosphorylation and functional inactivation of TSC2 by Erk. Implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
7. Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
8. Kenerson H., Dundon T.A., and Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57 (2005) 67-75
9. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients. Results from five multicenter studies. Clin Transplant 18 (2004) 446-449
10. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11 (2005) 5319-5328
11. Guba M., Yezhelvev M., Eichhorn M.E., et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the present of VEGF. Blood 105 (2005) 4463-4469
12. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis. Involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
13. El-Hashemite N., Zhang H., Walker V., et al. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models. Synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 64 (2004) 3436-3443
14. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759